Payment overview · 2025
General Payments
$151.78
2 reported records · 2 companies
Healthcare provider profile · identity verified
Bryan G Laura, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EVANSVILLE, IN · NPI 1346227725
Verified facts
What the public records show
CMS Open Payments records show Bryan G Laura, MD received $151.78 in general payments during 2025 across 2 reported records.
INTUITIVE SURGICAL, INC. accounted for 87.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $132.37 | 87.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.41 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.78 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $132.37 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 355 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 291 | 35 |
| Alprazolam | Alprazolam | 274 | 59 |
| Lisinopril | Lisinopril | 244 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 68 |
| Omeprazole | Omeprazole | 235 | 62 |
| Tramadol Hcl | Tramadol Hcl | 224 | 54 |
| Losartan Potassium | Losartan Potassium | 205 | 58 |
| Simvastatin | Simvastatin | 197 | 52 |
| Alendronate Sodium | Alendronate Sodium | 181 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 43 |
| Sertraline Hcl | Sertraline Hcl | 176 | 41 |
| Furosemide | Furosemide | 174 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 37 |
| Gabapentin | Gabapentin | 170 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 40 |
| Metformin Hcl | Metformin Hcl | 152 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 44 |
| Meloxicam | Meloxicam | 144 | 32 |
| Prednisone | Prednisone | 139 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | 35 |
| Carvedilol | Carvedilol | 123 | 29 |
| Allopurinol | Allopurinol | 120 | 34 |
| Temazepam | Temazepam | 119 | 19 |
| Methylprednisolone | Methylprednisolone | 117 | 82 |
| Clonazepam | Clonazepam | 109 | 18 |
| Trazodone Hcl | Trazodone Hcl | 102 | 30 |
| Metformin Hcl Er | Metformin Hcl | 97 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 25 |
| Azithromycin | Azithromycin | 87 | 73 |
| Potassium Chloride | Potassium Chloride | 86 | 23 |
| Lorazepam | Lorazepam | 84 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 69 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 22 |
| Glimepiride | Glimepiride | 62 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 43 |
| Clonidine Hcl | Clonidine Hcl | 57 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | suppressed |
| Ondansetron Odt | Ondansetron | 56 | 22 |
| Finasteride | Finasteride | 55 | 16 |
| Atenolol | Atenolol | 54 | 12 |
| Cephalexin | Cephalexin | 54 | 34 |
| Eliquis | Apixaban | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Ezetimibe | Ezetimibe | 51 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 18 |
| Estradiol | Estradiol | 46 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Bupropion Xl | Bupropion Hcl | 44 | 11 |
| Valacyclovir | Valacyclovir Hcl | 41 | 17 |
| Diazepam | Diazepam | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Amoxicillin | Amoxicillin | 35 | 21 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 19 |
| Fluconazole | Fluconazole | 33 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 19 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | 11 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.78 · 2 records | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System, ELIQUIS | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error